Ligand Pharmaceuticals

AI Score

XX

Unlock

108.42
3.60 (3.43%)
At close: Apr 02, 2025, 3:59 PM
108.73
0.29%
After-hours: Apr 02, 2025, 04:20 PM EDT

Company Description

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide.

Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.

The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression.

In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension.

The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases.

Further, it sells Captisol materials.

The company was incorporated in 1987 and is headquartered in Emeryville, California.

Ligand Pharmaceuticals
Ligand Pharmaceuticals logo
Country United States
IPO Date Nov 18, 1992
Industry Biotechnology
Sector Healthcare
Employees 68
CEO Todd C. Davis Ph.D.

Contact Details

Address:
5980 Horton Street
EmeryVille, California
United States
Website https://www.ligand.com

Stock Details

Ticker Symbol LGND
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000886163
CUSIP Number 53220K504
ISIN Number US53220K5048
Employer ID 77-0160744
SIC Code 2834

Key Executives

Name Position
Scott M. Plesha Chief Executive Officer of Pelthos Therapeutics
Todd C. Davis Ph.D. Chief Executive Officer & Director
Andrew T. Reardon J.D. Chief Legal Officer
Octavio Espinoza Chief Financial Officer
Dr. Karen R. Reeves M.D. Senior Vice President of Investments & Head of Clinical Strategy
Dr. Keith Marschke Ph.D. Senior Vice President of Biology & Scientific Affairs
Dr. Vincent D. Antle Ph.D. Senior Vice President of Technical Operations & QA - Capitsol
Patrick Lucy Senior Vice President & CBO Protein Expression Business
Paul J. Hadden Senior Vice President of Investments & Business Development
Richard B. Baxter Senior Vice President of Investment Operation

Latest SEC Filings

Date Type Title
Mar 06, 2025 4 Filing
Mar 06, 2025 4 Filing
Mar 06, 2025 4 Filing
Feb 28, 2025 10-K Annual Report
Feb 27, 2025 8-K Current Report
Feb 25, 2025 8-K Current Report
Feb 19, 2025 4 Filing
Feb 19, 2025 4 Filing
Feb 19, 2025 4 Filing
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing